Panacea Biotec
- Market cap
- ₹ 1,917 Cr.
- P/E
- 4.5x
- P/B
- 2.4x
- 52-week range
- 292.4 – 647
- ROE
- −2%
- ROCE
- −2%
- Dividend yield
- 0%
- Debt / equity
- 0.03
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Panacea Biotec Limited is an India-based pharmaceutical and biotechnology company with research, manufacturing and marketing capabilities. The Company is engaged in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food and nutrition products in India and international markets. Its segments include vaccines and pharmaceutical formulations and nutrition. Panacea Biotec specializes in complex generics, vaccines, and novel drug delivery platforms. Its vaccine portfolio includes EasySix (DTwP-Hib-HepB-IPV), EasyFive-TITM (DTwP-Hib-HepB), EasyFour-TI (DTwP-Hib), EasyFourPol (DTwP-IPV) and Bivalent oral polio vaccine (type-1 and type-3). Its pipeline vaccines include NucoVac 11, DengiALL and Td (tetanus and diphtheria - reduced). Its pharmaceutical formulation products include Sitcom Tablets and Sitcom Cream. Its nutrition product brand names include ChilRun full, ChilRun 7+ and ChilRun full NoSucrose.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Panacea Biotec against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)4.5 against a typical 34.3: cheaper than most peers (1st = cheapest).5th of 220
- Sales growth+19.7% against a typical +15.6% from a year earlier.81st of 197
- Profit growth−44.4% against a typical +18.9% from a year earlier.128th of 160
- Share price, 3 months−22.2% against a typical −0.5%.185th of 200
- Size₹ 1,917.2 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).73rd of 199
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 13 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 30 May 2026 | Financial Results/Dividend | PANACEABIO : 30-May-2026 : The Company has informed the Exchange that a Board meeting to be held on May 29, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on May 30, 2026, To consider and approve the financial results for the period ended March 31, 2026 and recommendation / passing over of dividend |
| 29 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 11 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 14 Nov 2025 | Financial Results | To consider and approve the unaudited financial results for the quarter and half year ended September 30, 2025 |
| 14 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 143 | 151 | 136 | 116 | 147 | 163 | 133 | 167 | 141 | 165 | 167 | 200 |
| Expenses | 147 | 151 | 143 | 130 | 140 | 156 | 159 | 168 | 159 | 153 | 164 | 194 |
| Operating Profit | −4 | −0 | −6 | −14 | 7 | 8 | −27 | −1 | −18 | 12 | 3 | 6 |
| OPM % | −2.5% | −0.1% | −4.4% | −12.1% | 4.8% | 4.9% | −20.3% | −0.7% | −12.6% | 7.1% | 1.5% | 2.8% |
| Other Income | 6 | 8 | 14 | 7 | 7 | 6 | 36 | 17 | 9 | 5 | 5 | 7 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 |
| Depreciation | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 8 | 8 |
| Profit before tax | −8 | −2 | −2 | −17 | 5 | 4 | −0 | 7 | −19 | 6 | −1 | 4 |
| Tax % | 6.6% | 33.3% | −6.1% | −6.9% | 1.1% | −1.4% | 4,875% | 39.6% | −26.9% | 40.1% | −20% | 38.4% |
| Net Profit | −8 | −2 | −2 | −16 | 5 | 4 | −2 | 4 | −14 | 4 | −1 | 2 |
| EPS in Rs | −1.35 | −0.37 | −0.32 | −2.58 | 0.78 | 0.74 | −0.31 | 0.66 | −2.27 | 0.65 | 0.08 | 0.38 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 0%
- 5 Years
- 0%
- 3 Years
- 12%
- TTM
- 10%
- 10 Years
- 5%
- 5 Years
- 13%
- 3 Years
- 21%
- TTM
- 43%
- 10 Years
- 15%
- 5 Years
- 6%
- 3 Years
- 37%
- TTM
- —
- 10 Years
- —
- 5 Years
- −10%
- 3 Years
- −3%
- TTM
- —
Peers
Listed companies in the same business.
| Panacea Biotec | ₹ 329.95 | ₹ 1,917 Cr. | 4.5x | 2.4x | −2% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Rajesh Jain
- Executive Chairman of the Board, Managing Director
- Vinod Goel
- Group Chief Financial Officer, Head Legal & Corporate Governance
- Ankesh Jain
- Compliance Officer, Executive Director, Company Secretary
- Sandeep Jain
- Joint Managing Director, Executive Director
- Harshet Jain
- Whole Time Director
- Sanjay Trehan
- Director - Technical & Compliances
Prices are delayed and for information only. Nothing on this page is investment advice.